Apellis - Latest News and Information
APLS
Apellis is a global biopharmaceutical company developing life-changing therapies that target the complement system, focusing on diseases driven by excessive activation of the complement cascade. The company emphasizes C3-targeted therapies across areas such as hematology, ophthalmology, and nephrology, with a research and development pipeline spanning clinical trials and rare diseases. Headquartered with global reach, Apellis communicates a patient-centric mission and a commitment to advancing science in complement biology.
Pharmaceutical Executive Daily: Trump Administration Delays Appeal of Federal Ruling Blocking Vaccine Policy Overhaul
Roth/MKM Downgrades Apellis Stock Rating on Biogen Acquisition
Biogen to Acquire Apellis for $5.6 B, Shares Jump 136% on Deal
100% Pharma Tariffs, Lilly's Oral GLP-1 Approval, and a $12B Week in Biotech M&A – This Week in Biotech #94
Apellis Pharmaceuticals (APLS) Hits 2-Year High on 140% Upside From Biogen Merger
